Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve, a spray-type finasteride-based hair loss treatment, in Korea.

Boryung will exclusively market Almirall's spray-type hair loss treatment, Finjuve, in Korea.
Boryung will exclusively market Almirall's spray-type hair loss treatment, Finjuve, in Korea.

The agreement will give Boryung exclusive sales rights for Finjuve in Korea.

Finjuve, developed by Almirall, a global pharmaceutical company, is the world's first spray-type hair loss drug that uses finasteride. The treatment uses a topical method by spraying the treatment directly on the scalp at the hair loss area.

The treatment minimizes the effect on the body compared to oral finasteride treatment and improves safety. It also has equivalent efficacy to oral treatments.

Also, as Finjuve contains a water-soluble semi-synthetic polymer with high skin affinity, finasteride, the main ingredient, can penetrate deeply into the dermis of the scalp.

Through a clinical trial, Almirall found that after 24 weeks of administration, the number of hairs in a specific area of ​​the Finjuve-administered group increased three times than before.

The Finjuve-administered group also showed an equivalent level of efficacy compared to an oral finasteride 1mg, the most widely used treatment for male pattern hair loss.

Besides, Finjuve showed a blood concentration of 1/100 of that of the oral finasteride 1mg group and showed significantly less effect on the human body.

"Finjuve maintains the efficacy of oral finasteride 1mg, which has the largest prescription amount in the Korean male hair loss treatment market, but improves safety by lowering the blood concentration to 1/100 compared to oral formulations through formulation improvement," said Jung Woong-jae, head of Boryung’s Rx Division. "Based on proven safety, it will be a good treatment option for patients suffering from hair loss."

Copyright © KBR Unauthorized reproduction, redistribution prohibited